New injection aims to tackle Alzheimer's at its roots

NCT ID NCT07221344

Recruiting now Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called ARO-MAPT-SC in healthy people and those with early Alzheimer's. The goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection under the skin. The trial is still in early stages, so it focuses on safety and dosing, not yet on curing the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARO-MAPT-SC (a drug given by injection under the skin)
What this could lead to: If successful, this could point toward a treatment that slows or stops early Alzheimer's disease by targeting a key protein in the brain.
What could go wrong: This is an early-phase trial with only 112 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease early-onset autosomal dominant Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE ALZHEIMER DISEASE, EARLY ONSET

Contacts and locations

Locations

Research Site 1
RECRUITING

Grafton, Auckland, 1010, New Zealand
Research Site 2
RECRUITING

Toronto, Ontario, M3B2S7, Canada
Research Site 3
RECRUITING

East York, Ontario, M4G 3E8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.